MIGUEL JOSE
MARTIN JIMÉNEZ
Profesor emérito
Ludwig Maximilian University of Munich
Múnich, AlemaniaPublikationen in Zusammenarbeit mit Forschern von Ludwig Maximilian University of Munich (11)
2022
-
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
npj Precision Oncology, Vol. 6, Núm. 1
2021
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
Biomarker analyses of response to cyclin-dependent kinase 4/6 inhibition and endocrine therapy in women with treatment-naïve metastatic breast cancer
Clinical Cancer Research, Vol. 26, Núm. 1, pp. 110-121
-
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2
Clinical Breast Cancer, Vol. 20, Núm. 2, pp. e173-e180
2019
2018
-
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: Results from the PALOMA-2 trial
Annals of Oncology, Vol. 29, Núm. 4, pp. 888-894
-
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 1, pp. 115-126
2016
-
Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel
Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390
-
Palbociclib and letrozole in advanced breast cancer
New England Journal of Medicine, Vol. 375, Núm. 20, pp. 1925-1936
2011
-
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials
The Lancet, Vol. 378, Núm. 9793, pp. 771-784
2010
-
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast
Journal of the National Cancer Institute - Monographs, Vol. 41, pp. 162-177